Anavex Life Sciences Corp
Gesloten
SectorGezondheidszorg
3.34 1.83
Overzicht
Wijziging aandelenprijs
24u
Min
3.2800000000000002
Max
3.39
Inkomsten | 4.1M -5.7M |
|---|---|
EPS | -0.06 |
Werknemers | 34 |
EBITDA | -821K -6.5M |
Volgende Winsten | 11 aug 2026 |
|---|
Marktkapitalisatie | 42M 273M |
|---|---|
Vorige openingsprijs | 1.51 |
Vorige sluitingsprijs | 3.34 |
Nieuwssentiment
By Acuity
86%
14%
321 / 340 Rangschikking in Healthcare
Anavex Life Sciences Corp Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Anavex Life Sciences Corp Prognose
Sentiment
By Acuity
321 / 340 Rangschikking in Gezondheidszorg
Nieuwssentiment
Zeer Sterk Bearish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Boven gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Anavex Life Sciences Corp
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
